Generic versus disease-specific measures of health-related quality of life in systemic lupus erythematosus

Journal of Rheumatology

Volumn 38, Issue 9, 2011, Pages 1821-1823

  Strand, Vibeke ^a   Chu, Alvina D ^b  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABETIMUS; BELIMUMAB; EPRATUZUMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ORAL CONTRACEPTIVE AGENT; PRASTERONE;

CLINICAL ASSESSMENT TOOL; DISEASE ACTIVITY; DISEASE SEVERITY; EDITORIAL; HEALTH RELATED QUALITY OF LIFE SCORE; HORMONE SUBSTITUTION; HUMAN; LIFE EXPECTANCY; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RELAPSE; REMISSION; RHEUMATIC DISEASE; SCORING SYSTEM; SHORT FORM 36; SYMPTOM; SYSTEMIC LUPUS ERYTHEMATOSUS; VALIDITY; WELLBEING;

FEMALE; HEALTH STATUS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 80052310109     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.110766     Document Type: Editorial

References (24)

1. Strand V, Russell AS. Workshop report: WHO/ILAR Taskforce on Quality of Life. J Rheumatol 1997;24:1630-3. (Pubitemid 27320709)
2. Baker K., Pope J. Employment and work disability in systemic lupus erythematosus:A systematic review. Rheumatology 2009;48:281-4.
3. Kiani A.N., Petri M. Quality-of-life measurements versus disease activity in systemic lupus erythematosus. Curr Rheumatol Rep 2010;12:250-8.
4. Thumboo J, Strand V. Health-related quality of life in patients with systemic lupus erythematosus: an update. Ann Acad Med Singapore 2007;36:115-22. (Pubitemid 46640263)
5. Strand V, Aranow C, Cardiel MH, Alarcon-Segovia D, Furie R, Sherrer Y, et al. Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo. Lupus 2003;12:677-86. (Pubitemid 37173664)
6. Strand V, Crawford B. Improvement in health-related quality of life in patients with SLE following sustained reductions in anti-dsDNA antibodies. Expert Rev Pharmacoecon Outcomes Res 2005;5:317-26. (Pubitemid 40894969)
7. Strand V., Crawford B., Singh J., Choy E., Smolen J.S., Khanna D. Use of "spydergrams" to present and interpret SF-36 health-related quality of life data across rheumatic diseases. Ann Rheum Dis 2009;68:1800-4.
8. Strand V., Levy R.A., Cervera R., Petri M., Rudge H., Pineda L., et al. for the BLISS-52 and -76 Study groups. Belimumab, a BlyS-specific inhibitor, improved fatigue and SF-36 physical and mental component summary scores in patients with SLE:BLISS-52 and -76 Studies [abstract]. Arthritis Rheum 2010;62 Suppl:S773.
9. Strand V., Gladman D., Isenberg D., Petri M., Smolen J.S., Tugwell P. Endpoints:Consensus recommendations from OMERACT IV. Outcome Measures in Rheumatology. Lupus 2000;9:322-7.
10. Gladman D, Urowitz MB, Ong A, Gough J, MacKinnon A. Lack of correlation among the 3 outcomes describing SLE: disease activity, damage and quality of life. Clin Exp Rheumatol 1996;14:305-8. (Pubitemid 26290872)
11. McElhone K, Abbott J, Shelmerdine J, Bruce IN, Ahmad Y, Gordon C, et al. Development and validation of a disease-specific health-related quality of life measure, the LupusQol, for adults with systemic lupus erythematosus. Arthritis Rheum 2007; 57:972-9. (Pubitemid 47237322)
12. McElhone K., Castelino M., Abbott J., Bruce I.N., Ahmad Y., Shelmerdine J., et al. The LupusQoL and associations with demographics and clinical measurements in patients with systemic lupus erythematosus. J Rheumatol 2010;37:2273-9.
13. Jolly M., Pickard A.S., Wilke C., Mikolaitis R.A., Teh L.S., McElhone K., et al. Lupus-specific health outcome measure for US patients:The LupusQoL-US version. Ann Rheum Dis 2010;69:29-33.
14. Gonzalez-Rodriguez V., Peralta-Ramirez M.I., Navarrete-Navarrete N., Callejas-Rubio J.L., Santos Ruiz A.M., Khamashta M. Adaptation and validation of the Spanish version of a disease specific quality of life measure in patients with systemic lupus erythematosus:The Lupus quality of life. Med Clin (Barc) 2010;134:13-6.
15. Doward L.C., McKenna S.P., Whalley D., Tennant A., Griffiths B., Emery P., et al. The development of the L-QoL:A quality-of-life instrument specific to systemic lupus erythematosus. Ann Rheum Dis 2009;68:196-200.
16. Leong KP, Kong KO, Thong BY, Koh ET, Lian TY, Teh CL, et al. Development and preliminary validation of a systemic lupus erythematosus-specific quality-of-life instrument (SLEQOL). Rheumatology 2005;44:1267-76. (Pubitemid 41487960)
17. Ow Y.L.M., Thumboo J., Cella D., Cheung Y.B., Fong K.Y., Wee H.L. Domains of health related quality of life important and relevant to multiethnic English speaking Asian SLE patients:A focus group study. Arthritis Care Res 2011;63:899-908.
18. Jolly M., Pickard A.D., Fogg L., Wilke C.T., Lin H.Q., Mikolaitis R.A., et al. US Patient Derived Lupus-Specific Patient Reported Outcome Measure (Lupus-PRO©):Validity and reliability [abstract]. Arthritis Rheum 2008;58 Suppl:S805.
19. Jolly M., Kosinski M., Garris C.P., Jhingran P.M., Mikolaitis R.A., Dennis G., et al. Development of the Lupus Impact Tracker™*:A tool for patients and HCPs to assess and monitor the impact of systemic lupus erythematosus (SLE) [abstract]. Ann Rheum Dis 2011;70 Suppl 3:501.
20. Jolly M., Kosinski M., Garris C.P., Jhingran P.M., Mikolaitis R.A., Dennis G., et al. Validation of the Lupus Impact Tracker™*:A tool for patients and HCPs to assess and monitor the impact of systemic lupus erythematosus (SLE) [abstract]. Ann Rheum Dis 2011;70 Suppl 3:425.
21. Touma Z., Gladman D.D., Ibañez D., Urowitz M.B. Is there an advantage over SF-36 with a quality of life measure that is specific to systemic lupus erythematosus? J Rheumatol 2011;38:1898-905.
22. Touma Z., Urowitz M.B., Taghavi-Zadeh S., Gladman D.D. Comparison of Lupus Quality of Life and SF-36 questionnaires in lupus patients with moderate to severe disease activity [abstract]. Ann Rheum Ds 2011;70 Suppl 3:698.
23. Hanly J.G., Urowitz M.B., Jackson D., Bae S.C., Gordon C., Wallace D.J., et al. SF-36 summary and subscale scores are reliable outcomes of neuropsychiatric events in SLE. Ann Rheum Dis 2011;70:961-7.
24. Wolfe F., Michaud K., Li T., Katz R.T. EQ-5D and SF-36 quality of life measures in systemic lupus erythematosus:Comparisons with rheumatoid arthritis, noninflammatory rheumatic disorders, and fibromyalgia. J Rheumatol 2010;37:296-304.